Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2018

28.06.2018 | Translational Research and Biomarkers

Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers

verfasst von: Amanda N. Graff-Baker, MD, Javier I. J. Orozco, MD, Diego M. Marzese, PhD, Matthew P. Salomon, PhD, Dave S. B. Hoon, PhD, Melanie Goldfarb, MD, MSc, FACS, FACE

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Molecular alterations impact tumor prognosis and response to treatment. This study was designed to identify transcriptomic and epigenomic signatures of breast cancer (BC) tumors from patients with any prior malignancy.

Methods

RNA-sequencing and genome-wide DNA methylation profiles from BCs were generated in the Cancer Genome Atlas project. Patients with secondary breast cancer (SBC) were separated by histological subtype and matched to primary breast cancer controls to create two independent cohorts of invasive ductal (IDC, n = 36) and invasive lobular (ILC, n = 40) carcinoma. Differentially expressed genes, as well as differentially methylated genomic regions, were integrated to identify epigenetically regulated abnormal gene pathways in SBCs.

Results

Differentially expressed genes were identified in IDC SBCs (n = 727) and in ILC SBCs (n = 261; Wilcoxon’s test; P < 0.05). In IDC SBCs, 105 genes were upregulated and hypomethylated, including an estrogen receptor gene, and 73 genes were downregulated and hypermethylated, including genes involved in antigen presentation and interferon response pathways (HLA-E, IRF8, and RELA). In ILC SBCs, however, only 17 genes were synchronously hypomethylated and upregulated, whereas 46 genes hypermethylated and downregulated. Interestingly, the SBC gene expression signatures closely corresponded with each histological subtype with only 1.51% of genes overlapping between the two histological subtypes.

Conclusions

Differential gene expression and DNA methylation signatures are seen in both IDC and ILC SBCs, including genes that are relevant to tumor growth and proliferation. Differences in gene expression signatures corresponding with each histological subtype emphasize the importance of disease subtype-specific evaluations of molecular alterations.
Literatur
1.
Zurück zum Zitat Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMed Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):271–89.CrossRefPubMed
2.
Zurück zum Zitat Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122(1):116–23.CrossRefPubMed Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122(1):116–23.CrossRefPubMed
3.
Zurück zum Zitat Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–7.CrossRefPubMedPubMedCentral Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol. 2017;3(11):1554–7.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121(8):1295–302.CrossRefPubMed Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121(8):1295–302.CrossRefPubMed
5.
Zurück zum Zitat Behrens C, Travis LB, Wistuba, II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin’s disease. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1027–35.PubMed Behrens C, Travis LB, Wistuba, II, et al. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin’s disease. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1027–35.PubMed
6.
Zurück zum Zitat Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin’s lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010;28(34):5088–96.CrossRefPubMedPubMedCentral Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin’s lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010;28(34):5088–96.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin’s lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011;29(18):2466–73.CrossRefPubMedPubMedCentral Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin’s lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011;29(18):2466–73.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, et al. Epigenetic profiling for the molecular classification of metastatic brain tumors. bioRxiv. 2018. Orozco JIJ, Knijnenburg TA, Manughian-Peter AO, et al. Epigenetic profiling for the molecular classification of metastatic brain tumors. bioRxiv. 2018.
9.
Zurück zum Zitat Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Molecular bioSystems. 2016;12(2):477–9.CrossRefPubMed Yu G, He QY. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Molecular bioSystems. 2016;12(2):477–9.CrossRefPubMed
11.
Zurück zum Zitat Feng M, Bao Y, Li Z, et al. RASAL2 activates RAC1 to promote triple-negative breast cancer progression. J Clin Invest. Dec 2014;124(12):5291–304.CrossRefPubMedPubMedCentral Feng M, Bao Y, Li Z, et al. RASAL2 activates RAC1 to promote triple-negative breast cancer progression. J Clin Invest. Dec 2014;124(12):5291–304.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Gomez LC, Sottile ML, Guerrero-Gimenez ME, et al. TP73 DNA methylation and upregulation of DeltaNp73 are associated with an adverse prognosis in breast cancer. J Clin Pathol. 2018;71(1):52–8.CrossRefPubMed Gomez LC, Sottile ML, Guerrero-Gimenez ME, et al. TP73 DNA methylation and upregulation of DeltaNp73 are associated with an adverse prognosis in breast cancer. J Clin Pathol. 2018;71(1):52–8.CrossRefPubMed
13.
Zurück zum Zitat Marzese DM, Gago FE, Orozco JI, Tello OM, Roque M, Vargas-Roig LM. Aberrant DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report. J Med Case Rep. 2011;5:516.CrossRefPubMedPubMedCentral Marzese DM, Gago FE, Orozco JI, Tello OM, Roque M, Vargas-Roig LM. Aberrant DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report. J Med Case Rep. 2011;5:516.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Molec Cell Probes. 2010;24(5):271–80.CrossRefPubMed Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Molec Cell Probes. 2010;24(5):271–80.CrossRefPubMed
15.
Zurück zum Zitat Marzese DM, Hoon DS, Chong KK, et al. DNA methylation index and methylation profile of invasive ductal breast tumors. J Molec Diagnos. 2012;14(6):613–22.CrossRef Marzese DM, Hoon DS, Chong KK, et al. DNA methylation index and methylation profile of invasive ductal breast tumors. J Molec Diagnos. 2012;14(6):613–22.CrossRef
16.
Zurück zum Zitat Urrutia G, Laurito S, Marzese DM, et al. Epigenetic variations in breast cancer progression to lymph node metastasis. Clin Exp Met. 2015;32(2):99–110.CrossRef Urrutia G, Laurito S, Marzese DM, et al. Epigenetic variations in breast cancer progression to lymph node metastasis. Clin Exp Met. 2015;32(2):99–110.CrossRef
17.
Zurück zum Zitat Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.CrossRef
18.
19.
Zurück zum Zitat Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690–705 e699. Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690–705 e699.
20.
Zurück zum Zitat Iida Y, Ciechanover A, Marzese DM, et al. Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-kappaB Pathway in Melanoma. Clin Cancer Res. 2017;23(16):4831–42.CrossRefPubMedPubMedCentral Iida Y, Ciechanover A, Marzese DM, et al. Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-kappaB Pathway in Melanoma. Clin Cancer Res. 2017;23(16):4831–42.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Bustos MA, Salomon MP, Nelson N, et al. Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer. Gen Data. 2017;12:14–6.CrossRef Bustos MA, Salomon MP, Nelson N, et al. Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer. Gen Data. 2017;12:14–6.CrossRef
22.
Zurück zum Zitat Marzese DM, Witz IP, Kelly DF, Hoon DS. Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. Epigenomics. 2015;7(8):1303–11.CrossRefPubMed Marzese DM, Witz IP, Kelly DF, Hoon DS. Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. Epigenomics. 2015;7(8):1303–11.CrossRefPubMed
23.
Zurück zum Zitat Marzese DM, Huynh JL, Kawas NP, Hoon DS. Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Gen Data. 2014;2:150–2.CrossRef Marzese DM, Huynh JL, Kawas NP, Hoon DS. Multi-platform genome-wide analysis of melanoma progression to brain metastasis. Gen Data. 2014;2:150–2.CrossRef
24.
Zurück zum Zitat Hoshimoto S, Takeuchi H, Ono S, et al. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. J Thorac Oncol. 2015;10(3):509–17.CrossRefPubMed Hoshimoto S, Takeuchi H, Ono S, et al. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome. J Thorac Oncol. 2015;10(3):509–17.CrossRefPubMed
25.
Zurück zum Zitat Wang J, Huang SK, Marzese DM, et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Ddermatol. 2015;135(2):532–41.CrossRef Wang J, Huang SK, Marzese DM, et al. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Ddermatol. 2015;135(2):532–41.CrossRef
26.
Zurück zum Zitat Marzese DM, Liu M, Huynh JL, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82–93.CrossRefPubMed Marzese DM, Liu M, Huynh JL, et al. Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res. 2015;28(1):82–93.CrossRefPubMed
27.
Zurück zum Zitat Marzese DM, Scolyer RA, Roque M, et al. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-oncology. 2014;16(11):1499–1509.CrossRefPubMedPubMedCentral Marzese DM, Scolyer RA, Roque M, et al. DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-oncology. 2014;16(11):1499–1509.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Marzese DM, Scolyer RA, Huynh JL, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Mol Gen. 2014;23(1):226–38.CrossRef Marzese DM, Scolyer RA, Huynh JL, et al. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Mol Gen. 2014;23(1):226–38.CrossRef
29.
30.
Zurück zum Zitat Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Gen. 2016;17(5):284–99.CrossRef Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Gen. 2016;17(5):284–99.CrossRef
31.
Zurück zum Zitat Winkelmann N, Schafer V, Rinke J, et al. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. J Cancer Res Clin Oncol. 2017;143(12):2511–9.CrossRefPubMed Winkelmann N, Schafer V, Rinke J, et al. Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies. J Cancer Res Clin Oncol. 2017;143(12):2511–9.CrossRefPubMed
32.
Zurück zum Zitat Chen JY, Luo CW, Lai YS, Wu CC, Hung WC. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis. 2017;6(8):e369.CrossRefPubMedPubMedCentral Chen JY, Luo CW, Lai YS, Wu CC, Hung WC. Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer. Oncogenesis. 2017;6(8):e369.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007;67(7):3301–9.CrossRefPubMed Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res. 2007;67(7):3301–9.CrossRefPubMed
Metadaten
Titel
Epigenomic and Transcriptomic Characterization of Secondary Breast Cancers
verfasst von
Amanda N. Graff-Baker, MD
Javier I. J. Orozco, MD
Diego M. Marzese, PhD
Matthew P. Salomon, PhD
Dave S. B. Hoon, PhD
Melanie Goldfarb, MD, MSc, FACS, FACE
Publikationsdatum
28.06.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6582-7

Weitere Artikel der Ausgabe 10/2018

Annals of Surgical Oncology 10/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.